Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16866502 | 0.88 | FOLH1 (0.51) | FOLH1ALDH1A1L3MBTL1HDAC1 | |
| SCHEMBL8211039 | 0.86 | ALDH1A1 (0.48) | FOLH1ALDH1A1HDAC1 | |
| SCHEMBL13437076 | 0.86 | FOLH1 (0.46) | FOLH1ALDH1A1HDAC1 | |
| SCHEMBL13437077 | 0.83 | FOLH1 (0.44) | FOLH1ALDH1A1HDAC1 | |
| SCHEMBL2628207 | 0.83 | CYP4F2 (0.40) | FOLH1CYP4F2CYP4A11 | |
| SCHEMBL18605543 | 0.83 | CYP4F2 (0.40) | FOLH1CYP4F2CYP4A11 | |
| SCHEMBL23038420 | 0.81 | POLB (0.57) | CYP4F2CYP4A11ALDH1A1L3MBTL1HDAC1 | |
| SCHEMBL27629127 | 0.80 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1L3MBTL1HDAC1 | |
| SCHEMBL20341529 | 0.80 | FOLH1 (0.65) | FOLH1ALDH1A1HDAC1 | |
| SCHEMBL21063617 | 0.80 | MAOA (0.47) | CYP4F2CYP4A11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2021146454-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021146458-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021146441-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| US-10821196-B2 | Substrate based PET imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10821196-B2 | Substrate based PET imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-2279011-A2 | SUBSTRATE BASED PET IMAGING AGENTS | Siemens Medical Solutions USA, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100074844-A1 | Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100074844-A1 | Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100074844-A1 | Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100074843-A1 | Novel Substrate Based PET Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100074843-A1 | Novel Substrate Based PET Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100074843-A1 | Novel Substrate Based PET Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2009134405-A2 | NOVEL SUBSTRATE BASED PET IMAGING AGENTS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134405-A2 | NOVEL SUBSTRATE BASED PET IMAGING AGENTS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134382-A2 | CYCLOPEPTIDES CONTAINING RGD MIMETICS AS IMAGING MARKERS FOR INTEGRINS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074843-A1 | Novel Substrate Based PET Imaging Agents | MPI, PIGO, SLC35B2 | FOLH1 139/4885CYP4F2 582/4885CYP4A11 3910/4885 |
| US-20100074844-A1 | Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins | ITGB3, ITGAV, ITGB1 | FOLH1 554/4885CYP4F2 4656/4885CYP4A11 4862/4885 |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | FOLH1 640/4885CYP4F2 4654/4885CYP4A11 3119/4885 |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | FOLH1 640/4885CYP4F2 4654/4885CYP4A11 3119/4885 |
| US-10821196-B2 | Substrate based PET imaging agents | MPI, PIGO, SLC35B2 | FOLH1 147/4885CYP4F2 532/4885CYP4A11 3643/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | FOLH1 640/4885CYP4F2 4654/4885CYP4A11 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.